Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695]
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris.[L11701,L11704,L11719] Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis.[L11716] Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms.[L11707,L11710,L11713] These include rickettsiae, _Mycoplasma pneumoniae_, _Chlamydia trachomatis_, _Chlamydophila psittaci_, _Chlamydia trachomatis_, _Ureaplasma urealyticum_, _Borrelia recurrentis_, _Haemophilus ducreyi_, _Yersinia pestis_, _Francisella tularensis_, _Vibrio cholerae_, _Campylobacter fetus_, _Brucella_ species, _Bartonella bacilliformis_, _Klebsiella granulomatis_, _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, _Haemophilus influenzae_, and _Kelbsiella_ species.[L11710]
Categories
Agents Causing Muscle Toxicity
Agents that produce neuromuscular block (indirect)
Alimentary Tract and Metabolism
Anti-Acne Preparations
Anti-Acne Preparations for Topical Use
Anti-Bacterial Agents
Anti-Infective Agents
Antibacterials for Systemic Use
Antiinfectives and Antiseptics for Local Oral Treatment
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682